Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206609 | 0.89 | TSHR (0.68) | TSHRELANECETPALDH1A1SRC | |
| SCHEMBL21343037 | 0.85 | TSHR (0.50) | TSHRELANECETPALDH1A1SRC | |
| SCHEMBL29248140 | 0.85 | ALDH1A1 (0.56) | TSHRELANECETPALDH1A1SRC | |
| SCHEMBL5379773 | 0.83 | TSHR (0.61) | TSHRELANECETPALDH1A1SRC | |
| SCHEMBL20123381 | 0.82 | TSHR (0.59) | TSHRELANECETPSRCNPC1 | |
| SCHEMBL233190 | 0.82 | TSHR (0.59) | TSHRELANECETPALDH1A1SRC | |
| SCHEMBL5907551 | 0.82 | TSHR (0.59) | TSHRELANECETPALDH1A1SRC | |
| SCHEMBL79996 | 0.81 | TSHR (0.63) | TSHRELANECETPALDH1A1SRC | |
| SCHEMBL4040892 | 0.81 | TSHR (0.81) | TSHRCETPALDH1A1SRCNPC1 | |
| SCHEMBL19986359 | 0.81 | TSHR (0.53) | TSHRELANECETPALDH1A1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120005497-A | Elastic anti-pollution flashover anti-freezing anti-corrosion coating material and preparation method thereof | 江西必可科技有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-118027098-A | Prodrugs of ospirimol and derivatives thereof, and preparation method and application thereof | 珠海安哲医药科技有限公司 | 2024-05-14 | — | — | CN | claimed |
| EP-2646035-A2 | PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4- METHYLPYRIDIN-2(1H)-ONE AND DERIVATIVES THEREOF | THE UNIVERSITY OF KANSAS (US) | 2013-10-09 | — | — | EP | claimed |
| US-20120142637-A1 | PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDIN-2-(1H)- ONE AND DERIVATIVES THEREOF | THE UNIVERSITY OF KANSAS (US) | 2012-06-07 | — | — | US | claimed |
| WO-2012075396-A2 | PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4- METHYLPYRIDIN-2(1H)-ONE AND DERIVATIVES THEREOF | THE UNIVERSITY OF KANSAS (US) | 2012-06-07 | — | — | WO | claimed |
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4606800-A1 | COMPOUND BASED ON ORYDALMINE STRUCTURE AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-12391650-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | H. LUNDBECK A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| US-20250197410-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-120019053-A | Compounds based on corydamine structures and uses thereof | 北京泰德制药股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-120005497-A | Elastic anti-pollution flashover anti-freezing anti-corrosion coating material and preparation method thereof | 江西必可科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-0966476-B1 | Quinazolinone compounds | UNIV NEWCASTLE VENTURES LTD (GB) | 2002-09-04 | — | — | EP | disclosed |
| US-20010025035-A1 | Water soluble prodrugs of hindered alcohols | UNIVERSITY OF KANSAS | 2001-09-27 | — | — | US | disclosed |
| EP-1102776-A1 | WATER SOLUBLE PRODRUGS OF HINDERED ALCOHOLS OR PHENOLS | THE UNIVERSITY OF KANSAS (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6204257-B1 | Water soluble prodrugs of hindered alcohols | UNIVERSTIY OF KANSAS | 2001-03-20 | — | — | US | disclosed |
| US-6156739-A | Quinazolinone compounds | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-12-05 | — | — | US | disclosed |
| WO-2000008033-A1 | WATER SOLUBLE PRODRUGS OF HINDERED ALCOHOLS OR PHENOLS | THE UNIVERSITY OF KANSAS (US) | 2000-02-17 | — | — | WO | disclosed |
| EP-0966476-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998033802-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448383-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TSHR 4522/4885ELANE 17/4885CETP 727/4885 |
| US-12391650-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | COMT, SLC6A2, MAOB | TSHR 2501/4885ELANE 2930/4885CETP 1477/4885 |
| US-20120142637-A1 | PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDIN-2-(1H)- ONE AND DERIVATIVES THEREOF | MCL1, MALT1, MYD88 | TSHR 2522/4885ELANE 963/4885CETP 1716/4885 |
| US-20010025035-A1 | Water soluble prodrugs of hindered alcohols | ADH1A, ADH5, ADH1C | TSHR 1482/4885ELANE 1437/4885CETP 1109/4885 |
| US-20250197410-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TSHR 4522/4885ELANE 17/4885CETP 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.